CytomX Therapeutics CTMX Other operating expenses
Other operating expenses at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about CytomX Therapeutics's other operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CytomX Therapeutics's other operating expenses?
- CytomX Therapeutics (CTMX) reported other operating expenses of $29.93M in Q1 2026.
- How has CytomX Therapeutics's other operating expenses changed year-over-year?
- CytomX Therapeutics's other operating expenses increased by 5.8% year-over-year, from $28.3M to $29.93M.
- What is the long-term trend for CytomX Therapeutics's other operating expenses?
- Over 4 years (2021 to 2025), CytomX Therapeutics's other operating expenses has grown at a -10.5% compound annual growth rate (CAGR), from $153.35M to $98.57M.
- What does other operating expenses mean?
- Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.